Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic Performance of ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and Breast MRI for Assessing Tumor Extent and Axillary Metastasis in Breast Cancer: A Histopathology-Referenced Retrospective Study.

European journal of nuclear medicine and molecular imaging·2026
Same author

The role of 18 F-FDG PET/CT SUVmax values in evaluating treatment response in hormone receptor-positive metastatic breast cancer patients receiving CDK4/6 inhibitor therapy.

Annals of nuclear medicine·2026
Same author

Baseline fluorodeoxyglucose PET/computed tomography volumetric parameters predict response to transarterial radioembolization in primary and metastatic liver tumors.

Nuclear medicine communications·2026
Same author

Performance of [68Ga]Ga-FAPI PET in Breast, Ovarian, and Cervical Cancers: A Systematic Review and Meta-Analysis.

Asian Pacific journal of cancer prevention : APJCP·2026
Same author

Discontinuation of Dialysis After ¹⁷⁷Lu-PSMA Therapy in mCRPC With Malignant Obstructive Uropathy.

Clinical nuclear medicine·2026
Same author

Diagnostic Value of <sup>68</sup>Ga-FAPI PET/CT Versus <sup>18</sup>F-FDG PET/CT in Laryngeal Cancer Staging.

Molecular imaging and radionuclide therapy·2026

Related Experiment Video

Updated: Jul 10, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Efficacy of 177Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and

Ebuzer Kalender1, Edanur Ekinci1, Umut Elboğa1

  • 1Department of Nuclear Medicine, School of Medicine, Gaziantep University, Gaziantep 27310, Turkey.

Biomedicines
|March 28, 2025
PubMed
Summary
This summary is machine-generated.

Lutetium-PSMA-617 (Pluvicto) therapy shows effectiveness in treating metastatic castration-resistant prostate cancer with liver metastases. Higher treatment intensity, indicated by more cycles, correlates with better outcomes and reduced PSA levels.

Keywords:
177Lu-PSMA-617PSASUVmaxliver metastasesmetastatic castration-resistant prostate canceroverall survivalprogression-free survivalradioligand therapy

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jul 10, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) presents a significant challenge, especially with liver involvement.
  • 177Lu-PSMA-617 (Pluvicto) is an approved radioligand therapy for mCRPC.

Purpose of the Study:

  • To assess the efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients with liver metastases.
  • To determine progression-free survival (PFS), overall survival (OS), and factors influencing treatment response.

Main Methods:

  • Retrospective analysis of 32 mCRPC patients with liver metastases treated with 177Lu-PSMA-617.
  • Collected data included PSA levels, liver SUVmax, therapy cycles, and survival outcomes.
  • Kaplan-Meier and regression analyses were used to evaluate survival and treatment response factors.

Main Results:

  • Median PFS was 6 months and median OS was 9 months.
  • Lower baseline PSA and liver SUVmax values were associated with partial regression (p=0.001 and p=0.008, respectively).
  • Increased 177Lu-PSMA-617 cycles correlated with improved response (p=0.010) and reduced liver SUVmax (p=0.043).

Conclusions:

  • 177Lu-PSMA-617 therapy is effective for mCRPC patients with liver metastases.
  • Greater treatment intensity (more cycles) is linked to better biochemical response (reduced PSA).
  • Findings support personalized treatment strategies and warrant further prospective investigation.